Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
ATHEROSCLEROSIS, vol.325, pp.99-109, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 325
- Publication Date: 2021
- Doi Number: 10.1016/j.atherosclerosis.2021.03.039
- Journal Name: ATHEROSCLEROSIS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
- Page Numbers: pp.99-109
- Hacettepe University Affiliated: Yes
Abstract
Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in highrisk and very-high-risk patients.